FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average	burden								
hours per response	e: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Burns James William					<u>A(</u>	2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [AGIO]									all applic Directo Officer	or (give title		10% Ov Other (s	vner	
(Last) 88 SIDN	(First) (Middle) IDNEY STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/10/2022									X Officer (give fine Other (specify below) Chief Legal Officer					
(Street) CAMBRIDGE MA 02139					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line) X	X Form filed by One Reporting Person Form filed by More than One Reporting					
(City)	(S	tate)	(Zip)			Person														
		Tab	le I - No	n-Deriv	ative	Sec	uriti	ies Ac	quired	, Dis	sposed o	of, or Be	enefic	ially	Owned	t				
Date			Date	Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr.		4. Securit Disposed	ies Acquire Of (D) (Ins	ed (A) o tr. 3, 4 a	and 5) Securition Beneficion Owned I		es ally Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D)	Pric	Reporte Transac (Instr. 3		ction(s)				
Common stock			02/10	/2022				M		1,833	A	\$	i0 ⁽¹⁾ 10),094		D			
Common stock 02/10/2				/2022	2022		F		643	D	\$31	L.425	9,451			D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	Date, Transact Code (In:		ion of		6. Date Exercisa Expiration Date (Month/Day/Year		е	7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		D S (I	Price of erivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Numb of Share	er						
Restricted stock units	(1)	02/10/2022			M			1,833	(2)		(2)	Common stock	1,83	33	\$ <mark>0</mark>	3,667		D		

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.

Remarks:

/s/ William Cook, as Attorney in Fact for James Burns

02/14/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.